Drug Type Universal CAR-T |
Synonyms CTB001(Nanjing Bioheng Biotech Co., Ltd.) |
Target |
Action inhibitors |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | IND Application | United States | 31 Aug 2022 | |
| Pancreatic Cancer | IND Application | China | 31 Aug 2022 | |
| Stomach Cancer | IND Application | United States | 31 Aug 2022 | |
| Stomach Cancer | IND Application | China | 31 Aug 2022 |





